Coupled with evidence that SREBF1 expression decreases type 2 diabetes risk by increasing serum adiponectin [54, 55] and the clear relevance of ADIPOQ to adiponectin production, there is now considerable support for their direct regulatory potential in metabolic risk (Fig. 6c, d). This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.